SAN FRANCISCO – As the healthcare infrastructure moves away from a one-size-fits-all model to a more personalized paradigm, and pharmacogenomic technologies shift the economic focus from the development of blockbusters to niche-busters, large drug companies’ sales prowess will be what saves them, according to Burrill & Company CEO Steven Burrill.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.